Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24

Futu NewsDec 21 02:43 · Ratings

Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital

Dow JonesDec 20 19:57 · Ratings

Stoke Therapeutics Initiated at Buy by Chardan Capital

Dow JonesDec 20 19:57 · Ratings

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

Yahoo FinanceDec 17 19:39

Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year

Simply Wall StDec 14 21:53

Cantor Fitzgerald Reiterates Overweight on Stoke Therapeuticsto Overweight

BenzingaDec 10 21:55